D. Ostertag

发表

Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

Masamichi Takahashi, K. Hiraoka, N. Kasahara, 2017, Neuro-oncology.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

D. Jolly, D. Ostertag, O. Diago, 2016, Human gene therapy methods.

Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model

W. Günzburg, H. Petznek, J. Hlavaty, 2013, Cancer Gene Therapy.

Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.

N. Kasahara, F. Hofman, H. Gruber, 2015, Human gene therapy.

JNK2 and IKKbeta are required for activating the innate response to viral infection.

M. Karin, Lufen Chang, Zhi-wei Li, 1999, Immunity.

Cell-Type-Specific Growth Restriction of Vesicular Stomatitis Virus polR Mutants Is Linked to Defective Viral Polymerase Function

D. Ostertag, J. Perrault, Traci M. Hoblitzell-Ostertag, 2006, Journal of Virology.

Function Linked to Defective Viral Polymerase Vesicular Stomatitis Virus polR Mutants Is Cell-Type-Specific Growth Restriction of

D. Ostertag, J. Perrault, Traci M. Hoblitzell-Ostertag, 2006 .

Cell type-specific growth restriction of vesicular stomatitis virus polR 1 mutants is linked to defective viral polymerase function 2 3 Running title : Cell type-specific growth restriction of VSV polR 4 5

D. Ostertag, J. Perrault, Traci M. Hoblitzell-Ostertag, 2006 .

Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients

Jay-Jiguang Zhu, A. Das, H. Gruber, 2018, Clinical Cancer Research.

Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer

N. Kasahara, D. Jolly, D. Ostertag, 2021, Expert opinion on biological therapy.

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

Harry E. Gruber, Joan M. Robbins, J. Hlavaty, 2011, Neuro-oncology.

Overproduction of Double-Stranded RNA in Vesicular Stomatitis Virus-Infected Cells Activates a Constitutive Cell-Type-Specific Antiviral Response

D. Ostertag, J. Perrault, Traci M. Hoblitzell-Ostertag, 2006, Journal of Virology.

MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.

N. Kasahara, C. Logg, Shuichi Kamijima, 2014, Human gene therapy.

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

William P. Accomando, T. Mikkelsen, T. Cloughesy, 2018, Neuro-oncology.

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

T. Mikkelsen, T. Cloughesy, L. Liau, 2016, Science Translational Medicine.

MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.

M. Hanna, D. Ostertag, O. Diago, 2016, Epigenomics.

EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Tina N. Davis, Forrest M Kievit, Atique U. Ahmed, 2013 .

SHEP1 partners with CasL to promote marginal zone B-cell maturation

E. Pasquale, R. Rickert, D. Ostertag, 2010, Proceedings of the National Academy of Sciences.

Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma

Ash A. Alizadeh, Aliz R. Rao, Aaron M. Newman, 2020, Clinical Cancer Research.

531. Intravenous Delivery of Toca 511 Gene Therapy in Combination with 5-Fluorocytosine for Intratumoral Production of 5-Fluorouracil in a Colon Cancer Metastasis Model

N. Kasahara, H. Gruber, J. Robbins, 2015 .

Intratumoral conversion of flucytosine to 5-fluorouracil using a novel MLV-based replication-competent retroviral vector carrying the cytosine deaminase gene (Toca 511) in an immune-competent model of glioblastoma.

W. Günzburg, H. Gruber, J. Robbins, 2010 .

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.

Aliz R. Rao, William P. Accomando, C. Bettegowda, 2020, JAMA oncology.

PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165)

T. Cloughesy, D. Tran, D. Schiff, 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

AT-02INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584)

Susan M. Chang, T. Cloughesy, L. Liau, 2014 .